| Bioactivity | Bcl-2-IN-8 is a potent anticancer agent. Bcl-2-IN-8 shows anti-proliferative activity against both drug-sensitive and drug-resistant cancer cells. Bcl-2-IN-8 induce apoptosis and cell cycle arrest at G1 phase. Bcl-2-IN-8 inhibits cell migration in a dose-dependent manner. Bcl-2-IN-8 has the potential for the research of triple negrative breast cancer[1]. |
| Invitro | Bcl-2-IN-8 (compound 4m) (48 h) shows selective cytotoxicity against MDA-MB-231, MCF-7/ADR, MCF-10A cells with IC50s of 0.51, 0.38, 3.56 µM, respectively[1].Bcl-2-IN-8 (0-8 µM; 24, 48, 72 h) inhibits cell proliferation in a dose-time dependently[1].Bcl-2-IN-8 (0-2 µM; 24 h) induces cell cycle arrest at G1 phase in MDA-MB-231 cells[1].Bcl-2-IN-8 (0-2 µM; 24 h) induces apoptosis in MDA-MB-231 cells[1].Bcl-2-IN-8 (0-3 µM; 24 h) up-regulates the expression of Bax, cytochrome c and down-regulates Bcl-2, P53 protein in a concentration dependently in MDA-MB-231 cells[1].Bcl-2-IN-8 (0-3 µM; 24 h) decreases the ΔΨm and induces ROS (reactive oxygen species) generation by activating the p38MAPK-Akt signaling pathway in MDA-MB-231 cells[1].Bcl-2-IN-8 (0-2 µM; 24 h) increases intracellular Ca2+ concentration from 9.9 treated with DMSO to 37.4 treated at 2 µM in MDA-MB-231 cells[1].Bcl-2-IN-8 (0-3 µM; 24 h) significantly inhibits migration in a dose-dependent manner in MDA-MB-231 cells[1].Bcl-2-IN-8 (0-3 µM; 24 h) increases the expression levels of Smad 7 but decreases the expression levels of p-Smad 3 in MDA-MB-231 cells[1]. Cell Cytotoxicity Assay[1]. Cell Line: |
| Name | Bcl-2-IN-8 |
| Formula | C36H44O6 |
| Molar Mass | 572.73 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |